Emerging Infectious Diseases (Sep 2015)

Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012

  • Susan Hariri,
  • Lauri E. Markowitz,
  • Nancy M. Bennett,
  • Linda Niccolai,
  • Sean D. Schafer,
  • Karen C. Bloch,
  • Ina U. Park,
  • Mary W. Scahill,
  • Pamela Julian,
  • Nasreen Abdullah,
  • Diane Levine,
  • Erin Whitney,
  • Elizabeth R. Unger,
  • Martin Steinau,
  • Heidi M. Bauer,
  • James I. Meek,
  • James L. Hadler,
  • Lynn Sosa,
  • Suzanne E. Powell,
  • Michelle L. Johnson,
  • HPV-IMPACT Working Group

DOI
https://doi.org/10.3201/eid2109.141841
Journal volume & issue
Vol. 21, no. 9
pp. 1557 – 1561

Abstract

Read online

In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. The project involved active population-based surveillance of cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ as well as associated HPV types in women >18 years of age residing in defined catchment areas; collecting relevant clinical information and detailed HPV vaccination histories for women 18–39 years of age; and estimating the annual rate of cervical cancer screening among the catchment area population. The first few years of the project provided key information, including data on HPV type distribution, before expected effect of vaccine introduction. The project’s success exemplifies the flexibility of EIP’s network to expand core activities to include emerging surveillance needs beyond acute infectious diseases. Project results contribute key information regarding the impact of HPV vaccination in the United States.

Keywords